Latest Hotspot

Innovent Starts Phase III Neoshot Trial with IBI310 Plus Sintilimab in Colon Cancer

2 April 2024
3 min read

Innovent Biologics, Inc., has publicly declared the initiation of a new phase in their clinical research, marking a significant milestone with the administration of the initial dose to a patient enrolled in their study. This marks the beginning of the treatment phase with IBI310, an anti-CTLA-4 monoclonal antibody, which is being tested alongside sintilimab. The study design is that of a randomized, multicenter Phase 3 trial, and it is focused on investigating the efficacy of these drugs as a pre-surgical therapy for patients with MSI-H/dMMR colon cancer that can be surgically removed.

👇Unlock in-depth information about this drug - its R&D Status, Core Patent, Clinical Trials, and Global Approval Status. Click on the image below and explore the latest data immediately.

图形用户界面, 文本, 应用程序, 电子邮件, Teams

描述已自动生成

In China, Neoshot represents the inaugural Phase 3 clinical investigation aimed at scrutinizing neoadjuvant immunotherapy for patients with MSI-H/dMMR colon cancer. The focus of this research is to ascertain the safety profile and therapeutic effectiveness of the combined use of IBI310 and sintilimab for neoadjuvant applications, which will be juxtaposed with the conventional adjuvant chemotherapeutic approach subsequent to complete surgical removal of MSI-H/dMMR colon cancer. The pivotal endpoints of the trial include the rate of pathologic complete response and the duration of event-free survival.

Earlier, during a Phase 1b randomized, controlled, and multicenter trial aimed at neoadjuvant treatment for individuals with surgically removable MSI-H/dMMR colon cancer, the group receiving both IBI310 and sintilimab displayed a notably greater pCR rate in comparison to patients treated solely with sintilimab. Importantly, none of the participants receiving the combination therapy were rendered inoperable owing to adverse effects, nor were there indications of heightened safety concerns. The outcomes of this Phase 1b study are expected to be disseminated at a forthcoming medical symposium or detailed in a peer-reviewed scientific publication.

Dr. Zhou Hui, a high-ranking executive at Innovent, has communicated the pressing necessity for novel neoadjuvant therapies for MSI-H/dMMR colon cancer that can be surgically removed within the Chinese context. Dr. Hui expressed contentment regarding the progress of the Phase 3 Neoshot trial, particularly with the initiation of treatment in the first patient. There is an anticipation for the upcoming conclusions of the trial, which are hoped to unveil greatly improved treatment avenues for MSI-H/dMMR colon cancer sufferers in China.

Developed in-house by Innovent, IBI310 is a highly specific, fully human monoclonal antibody. Its mode of action involves binding to cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), a critical step in disengaging the CTLA-4 mediated inhibitory effect on T cells, which in turn shores up T cell activation and expansion. Such a mechanism bolsters the immune-mediated onslaught against tumors, thereby delivering antineoplastic benefits.

👇Explore the most recent advancements in drug research, indications, organizations, clinical trials, results, and patents related to this target by clicking the image link below. Dive in to gain deeper insights!

图形用户界面, 文本, 应用程序

描述已自动生成

According to the data provided by the Synapse Database, As of March 28 2024, there are 117 investigational drugs for the CTLA-4 target, including 377 indications, 180 R&D institutions involved, with related clinical trials reaching 1638, and as many as 37186 patents.

IBI310 has the potential to treat a wide range of therapeutic areas. The drug has reached Phase 3 of clinical trials globally and in China, indicating its advanced stage of development. Additionally, its breakthrough therapy designation further emphasizes its potential to address critical medical needs.

图形用户界面, 文本, 应用程序

描述已自动生成

Tectonic Therapeutics Begins Phase I Trial of TX45 for Group II Pulmonary Hypertension in Patients with HFpEF
Latest Hotspot
3 min read
Tectonic Therapeutics Begins Phase I Trial of TX45 for Group II Pulmonary Hypertension in Patients with HFpEF
2 April 2024
Tectonic Therapeutics Commences First-Stage Clinical Trial Evaluating TX45 in Category II Lung High Blood Pressure among Subjects Having Conserved Ejection Fraction Cardiac Insufficiency.
Read →
FDA Approves Merck's WINREVAIR™ for Adult Pulmonary Arterial Hypertension
Latest Hotspot
3 min read
FDA Approves Merck's WINREVAIR™ for Adult Pulmonary Arterial Hypertension
1 April 2024
FDA Regulators Greenlight Merck's Novel WINREVAIR™ (sotatercept-csrk) Therapy for Treating Pulmonary Arterial Hypertension in Adult Patients.
Read →
What is Pharmacodynamics?
"What" Series
2 min read
What is Pharmacodynamics?
1 April 2024
Pharmacodynamics is the study of the biochemical and physiological effects of drugs on the body, including the mechanisms of action and the relationship between drug concentration and effect.
Read →
EU Approves Atamyo's ATA-200 Human Trials for Limb-Girdle MD 2C/R5
Latest Hotspot
3 min read
EU Approves Atamyo's ATA-200 Human Trials for Limb-Girdle MD 2C/R5
1 April 2024
Atamyo Pharma Secures Approval from European Regulators to Commence Human Trials of ATA-200, Their Innovative Genetic Treatment for Limb-Girdle Muscular Dystrophy 2C/R5.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.